Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference5 articles.
1. Towards peakless, reproducible and long-acting insulins: an assessment of the basal analogues based on isoglycaemic clamp studies;Heise;Diabetes Obes Metab,2007
2. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study;Porcellati;Diabetes Care,2007
3. Insulin detemir in combination with OADs improves glycaemic control and reduces hypoglycaemia, without weight gain, in type 2 patients previously treated with OADs plus bedtime NPH or insulin glargine: results from the PREDICTIVE™ study (P921);King;Diabet Med,2006
4. A randomized, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes;Rosenstock;Diabetologia,2008
5. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a treat-to-target study in people with type 2 diabetes;Raskin;Diabet Med,2006
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. References;Randomised Clinical Trials;2021-05-24
2. Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once‐nightly basal insulin;Diabetes, Obesity and Metabolism;2021-01-29
3. Detemir vs Glargine: Comparison of Inpatient Glycemic Control;Journal of Osteopathic Medicine;2019-02-01
4. Cumulative References;Sample Sizes for Clinical, Laboratory and Epidemiology Studies;2018-06-01
5. Non-Inferiority and Equivalence;Sample Sizes for Clinical, Laboratory and Epidemiology Studies;2018-06-01